Screening and Testing
The accuracy of AI programs to flag areas of concern on mammograms seems to depend on the diversity of the data used to create these programs.
After DCIS treatment, women who develop invasive breast cancer have the cancer found most often via mammogram or find it themselves, rather than during a doctor’s exam.
Regular mammograms reduce the risk of dying from breast cancer by more than 65%.
Women with a false-positive mammogram result had a 61% higher risk of breast cancer in the next 20 years.
Breast cancer screening for women in their 40s led to better survival for those who were diagnosed with the disease.
A mammogram plus an ultrasound was better than an AI-assisted mammogram at finding cancer in dense breasts.
Using artificial intelligence to help read mammograms found more cancers than the standard double reading by two radiologists.
Doctors need to consider more than breast density when deciding who should have supplemental ultrasound screening.
Black women with lower Oncotype DX Recurrence Scores had worse survival than women of other races with similar scores.
New ACR guidelines say all women — particularly women considered high risk — need a breast cancer risk assessment by age 25.
If an AI support system offers incorrect advice, it may affect how accurately radiologists read mammograms, no matter how experienced they are.
Research analyzing breast cancer death rates suggests Black women should start screening earlier than women of other races and ethnicities.
High out-of-pocket costs for follow-up imaging after an abnormal mammogram are challenging for many women.
A study has shown that 3D mammograms are best for breast cancer screening.
Breast MRI seems to be the best supplemental screening method for finding cancer in women with dense breasts.
Travel time to the nearest mammography center is long for many U.S. women, especially women in rural areas.
Four more years of follow-up continue to show that women with an Oncotype DX Breast Recurrence Score of 11-25 can safely skip chemotherapy; their risk or recurrence wasn’t higher than women who received chemotherapy.
Among people with Medicare, Black women had less access to newer mammogram technology than white women.
Aiming to clarify when women should start having mammograms, the National Comprehensive Cancer Network has released new guidelines for breast cancer screening and diagnosis that say all women age 40 and older at average risk of breast cancer should have annual mammograms.
Telling children that their mothers have a genetic risk of developing breast and ovarian cancer doesn’t affect their long-term quality of life.
Women from various racial and ethnic backgrounds, particularly Black women, had a higher risk of biopsy delays after an abnormal mammogram than white women.
In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease.
Rates of screening mammograms among women who’ve received breast cancer treatment have declined since 2009, especially among women ages 40 to 49.
Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.